Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · Real-Time Price · USD
1.370
+0.010 (0.74%)
At close: Dec 5, 2025, 4:00 PM EST
1.350
-0.020 (-1.46%)
After-hours: Dec 5, 2025, 7:53 PM EST

Telomir Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
9.910.012.370.020.01
Research & Development
1.412.241.570.830.13
Operating Expenses
11.3112.243.940.850.14
Operating Income
-11.31-12.24-3.94-0.85-0.14
Interest Expense
-0-4.34-1.64--
Interest & Investment Income
0.060.05---
EBT Excluding Unusual Items
-11.25-16.53-5.59-0.85-0.14
Other Unusual Items
---7.49--
Pretax Income
-11.25-16.53-13.07-0.85-0.14
Net Income
-11.25-16.53-13.07-0.85-0.14
Net Income to Common
-11.25-16.53-13.07-0.85-0.14
Shares Outstanding (Basic)
31302727-
Shares Outstanding (Diluted)
31302727-
Shares Change (YoY)
6.22%8.18%1.77%--
EPS (Basic)
-0.37-0.56-0.48-0.03-
EPS (Diluted)
-0.37-0.56-0.48-0.03-
EBIT
-11.31-12.24-3.94-0.85-0.14
Source: S&P Capital IQ. Standard template. Financial Sources.